This article is featured on The Association of Clinical Research Professionals (ACRP). Bradley D. Vince, DO and Sheldon H. Preskorn, MD discuss the process of developing a new molecular entity (NME) for FDA approval and strategies for establishing early efficacy. Key...
Most drugs are eliminated from the body through some combination of vital organs, such as the small intestine, liver and/or kidneys. The impaired function of either the liver or the kidney can significantly impact a drug’s pharmacokinetics (PK), influencing its...
At Dr. Vince Clinical Research we offer full-service Phase I-II trial execution that not only generates SMARTER FASTER DATA®, but does so through a building design that promotes greater overall wellness and long-term environmental sustainability. In order to discover...
At Dr. Vince Clinical Research, we utilize a forward-thinking model for Phase I studies supported by foundational pillars that completely reimagine research standards. Every inch of our facilities, and every step in our procedures, is intentionally designed, enabled...
CROs have a retention problem. Nearly 1 in 5 research sites have a turnover rate above 30%, and it has become increasingly difficult for many facilities and site management organizations to build a robust roster of specialized and proven professionals (1). While the...
The 21st century has opened up a new frontier for clinical research. Advances in data collection have produced massive data streams, and innovations in digital monitoring have made patient participation more flexible than ever. At the same time, Phase I research...
Recent Comments